Fludarabine
Pancreatic Carcinoma
Essen BiotechSmall moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
103 Active assets in the Pancreatic Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan OHSU Knight Cancer Institute | Phase 2/3 | BBB |
FLUOROURACILUM Northwestern University | Phase 2/3 | BBB |
Eloxatin OHSU Knight Cancer Institute | Phase 2/3 | BBB |
Gdc-0449 OHSU Knight Cancer Institute | Phase 2 | BB |
Capecitabine Zhejiang University | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →